scholarly journals MP34-12 THE ROLE OF SALVAGE LYMPH NODE DISSECTION IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A SINGLE CENTER EXPERIENCE

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Luca Boeri* ◽  
Vidit Sharma ◽  
Igor Frank ◽  
Stephen A. Boorjian ◽  
R. Houston Thompson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Node Dissection ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Salvage Lymph Node Dissection

scholarly journals Lymph Nodes Invasion of Marcille’s Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of “Marcillectomy”

2019 ◽  
Vol 103 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Antonio B. Porcaro ◽  
Giovanni E. Cacciamani ◽  
Marco Sebben ◽  
Alessandro Tafuri ◽  
Tania Processali ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Lymph Node Dissection ◽  
Pelvic Lymph Node Dissection ◽  
Pelvic Lymph Node ◽  
Node Dissection

Data of efficacy and toxicity for Radium-223 in patients with metastatic castration- resistant prostate cancer in real-life setting: A single-center experience

2018 ◽  
Vol 17 (14) ◽  
pp. e2851
Author(s):  
D. Akhoundova Sanoyan ◽  
D. Lorente Estelles ◽  
I. Burger ◽  
I. Engel ◽  
A. Mischo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real Life ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Radium 223 ◽  
Real Life Setting

scholarly journals The role of salvage lymph node dissection and PSMA-PET in recurrent prostate cancer

Gland Surgery ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 1080-1081
Author(s):  
Nikolaos Kalampokis ◽  
Nikolaos Grivas
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Lymph Node Dissection ◽  
Recurrent Prostate Cancer ◽  
Node Dissection ◽  
Psma Pet ◽  
Salvage Lymph Node Dissection

Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16050-e16050
Author(s):  
Atike Pinar ◽  
Ahmet Ozveren ◽  
Zeki Gokhan Surmeli ◽  
Ulus Ali Sanli ◽  
Ruchan Uslu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Castration Resistant Prostate Cancer ◽  
Prognostic Role ◽  
Lymphocyte Ratio ◽  
Castration Resistant

scholarly journals Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

2020 ◽  
Author(s):  
Yang Liu ◽  
Wen Long ◽  
Zitong Zhang ◽  
Lixin Mai ◽  
Sijuan Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Potential Benefit ◽  
Prognostic Index ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistance ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Significant Factors

Abstract Background: To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone.Methods: From February 2014 to February 2019, 149 mCRPC patients treated with abiraterone were identified. Patients receiving cRT before abiraterone failure (AbiRT group) were matched by one-to-two propensity score to patients without cRT before abiraterone failure (non-AbiRT group).Results: The median follow-up was 23.5 months. Thirty patients (20.1%) were in the AbiRT group, whereas 119 patients (79.9%) were in the non-AbiRT group. The 2-year OS of patients managed by AbiRT and non-AbiRT were 89.5% and 73.5%, respectively (P = 0.0003). On multivariate analysis, only AbiRT (HR, 0.17; 95%CI, 0.05–0.58; P = 0.004) and prognostic index (HR 2.71; 95% CI, 1.37–5.35; P = 0.004) were significant factors. After matching, AbiRT continued to be associated with improved OS (median OS not reached vs. 44.0 months, P = 0.009). Subgroup analysis revealed that patients aged ≤65 years (HR, 0.09; 95%CI, 0.01–0.65; P = 0.018), PSA ≤20 ng/mL (HR 0.29; 95% CI, 0.09–0.99; P = 0.048), chemotherapy-naïve upon abiraterone treatment (HR 0.20; 95% CI, 0.06–0.66; P = 0.008) and in intermediate prognosis groups by COU-AA-301 prognostic index (HR 0.13; 95% CI, 0.03-0.57; P = 0.007) had improved OS with AbiRT. Conclusions: cRT before resistance to abiraterone may improve survival in selected mCRPC patients: age ≤65 years old, chemotherapy-naïve, with PSA ≤20 ng/mL at the diagnosis of mCRPC and intermediate prognosis.

Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate

2015 ◽  
Vol 76 (3) ◽  
pp. 439-445 ◽  
Author(s):  
Roberto Petrioli ◽  
Edoardo Francini ◽  
Letizia Laera ◽  
Anna Ida Fiaschi ◽  
Roberto Ponchietti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases

2020 ◽  
Vol 22 (4) ◽  
pp. 437
Author(s):  
Anil Kapoor ◽  
NathanC Wong ◽  
Yuding Wang ◽  
Som Mukherjee ◽  
Sebastien Hotte ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Radium 223
Sign in / Sign up

Export Citation Format

Share Document